Background Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. Methods We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. Results Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR=2.041, 95% CI=1.235-3.373) and surgical resection (HR=0.504, 95% CI=0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancerspecific mortality, respectively. Median OS (41.2 vs. 20.3 months, p=0.012) and DFS (21.5 vs. 11.4 months, p=0.007) were significantly improved with the addition of surgery compared to definitive CXRT. Conclusions Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.
Introduction
The majority of esophageal adenocarcinoma patients present with locally advanced disease. 1, 2 This represents a significant disease burden at high risk of local and regional recurrence unless aggressive treatment is received. Trimodality therapy with neoadjuvant concurrent chemoradiation (CXRT; with or without induction chemotherapy) followed by esophagectomy is currently considered the optimal treatment as a means to achieve a complete resection, reduce recurrence and improve disease-free survival in medically able patients. [3] [4] [5] the appropriate role of surgery after patients achieve a clinical response to CXRT. 6 Furthermore, salvage esophageal resection has emerged as a viable option for select patients that present with locoregional recurrent disease after definitive CXRT. 7, 8 Perhaps because of these findings, we have noted a practice trend toward bimodality therapy with definitive CXRT in patients with locally advanced adenocarcinoma. Definitive CXRT treatment strategies, however, have not been rigorously evaluated in exclusively adenocarcinoma populations. In light of disparate data, medically able patients that are eligible for trimodality therapy are increasingly treated with definitive CXRT. 9 Strategies are needed to further identify groups of patients that may benefit from the addition of surgery (vs. observation) after successful completion of CXRT. We sought to quantify the benefit of surgery by comparing overall survival (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by surgery. Specifically, we hypothesized that surgery provides an additional OS and DFS benefit to locally advanced esophageal adenocarcinoma patients that successfully complete CXRT.
Methods

Study Population
We identified patients treated consecutively for esophageal adenocarcinoma at the University of Texas MD Anderson Cancer Center (MD Anderson) using a prospectively maintained database. This research was approved by the Institutional Review Board at MD Anderson (DR11-0298). Patients were diagnosed between January 2002 and December 2008, treated with neoadjuvant CXRT with or without induction chemotherapy, and all treatment was delivered at MD Anderson. Patients with synchronous cancers or cancer of the cervical esophagus were excluded.
All patients included in this study were staged as clinical stage (cStage) III (T3N1). Clinical staging was determined as follows: endoscopic ultrasound (EUS) for tumor depth, positron emission tomography (PET) scan and/or computed tomography (CT) scan and/or EUS for regional nodal involvement, and PET-CT scan for distant metastasis. Patients were classified according to the American Joint Committee on Cancer Staging Manual, 6th Edition. 10 Patients that met the inclusion criteria must have also been considered eligible for trimodality therapy both before and after neoadjuvant therapy. Medically inoperable patients with significant comorbidities or patients with medical contraindications to surgery were excluded. All patients were evaluated in a prospective multidisciplinary setting and were recommended as candidates for curative resection at the time of initial staging and physiologic assessment. After completing neoadjuvant therapy, patients underwent restaging evaluations and were reassessed for surgery. Any patient with suspected or proven distant metastasis (i.e., disease progression) or that died during neoadjuvant therapy was further excluded. The resulting study population consisted exclusively of trimodality-eligible patients who successfully completed neoadjvuant therapy and were considered appropriate surgical candidates.
Predictor Variables
Patient, tumor, and treatment-related variables were used in all survival analyses. Patient characteristics included age at diagnosis; sex (male, female); race/ethnicity (White, nonWhite); and comorbidity. Patient comorbidity severity was evaluated by calculating a Charlson score. 11 Primary cancerand treatment-associated complications for the index cancer were not included in the comorbidity score.
Tumor-and treatment-related variables included tumor length; tumor grade (well/moderately differentiated, poorly differentiated); CXRT sequence (induction chemotherapy followed by concurrent CXRT, concurrent CXRT); radiation dose; pre-and post-treatment standard uptake value (SUV) of the primary tumor on pre-and post-CXRT PET scans; and treatment with surgery. Recursive partitioning was used to determine appropriate cutoffs for PET SUV.
Statistical Analysis
Pearson chi-square tests or Fisher's exact tests were used to compare categorical characteristics; t tests or Wilcoxon rank-sum tests were used to compare continuous characteristics of the study population.
Univariate and multivariable Cox hazard regression models were used to identify significant predictors of OS and DFS. Univariate factors with a p value <0.25 were entered into a multivariable stepwise Cox proportional hazard regression model. Wald's stepwise selection with p= 0.10 was used as entry and removal probability until the final model for the data set was obtained. Final regression models were age-adjusted to account for potential differences between the two treatment groups.
We also compared median OS and DFS using the Kaplan-Meier method. OS was calculated from the day of first treatment until the last known date of follow-up or date of death and DFS from the day of first treatment until the first known date of disease recurrence or last known date of follow-up or date of death. Log-rank tests were used to compare the survival distributions.
Finally, propensity score matching was used to correct for baseline differences between treatment groups. This statistical methodology controls for potential selection bias associated with observational data by reducing bias related to the non-randomized assignment of treatment. 12 The propensity score reflects an individual patient's predicted probability of receiving treatment. Patients were matched on age, comorbidity score, tumor length, tumor grade, post-CXRT biopsy, and post-CXRT SUV.
Subgroup and Sensitivity Analysis
In addition to comparing the OS and DFS of patients treated with definitive CXRT and CXRT followed by surgery, we performed a subgroup analysis on patients considered clinical responders to CXRT. Clinical response was evaluated using the following criteria: (1) no evidence of disease progression on post-CXRT regional or distant PET; (2) negative post-CXRT biopsy; and (3) decrease in local pre-and post-CXRT SUV on PET scan ≥35 %. 13 Criteria were applied hierarchically. Any patients with evidence of physiologic change (e.g., radiation pneumonitis, esophagitis) and/or local SUV ≤5 on post-CXRT PET were evaluated on a case-by-case basis. Patients were classified as either responders or non-responders. Any patient with missing pre-or post-CXRT PET data or post-CXRT biopsy was excluded from the subgroup analysis. We compared the median OS of definitive CXRT responders and surgery responders using the Kaplan-Meier method.
We also performed a sensitivity analysis that included salvage resections as part of the definitive CXRT treatment group. The median OS of definitive CXRT (including salvage patients) and CXRT followed by surgery was compared using the Kaplan-Meier method.
Statistical calculations were performed using the Statistical Package for Social Sciences (SPSS, Chicago, IL). Statistical significance was accepted as p of 0.05 or less.
Results
We identified 207 potentially eligible cStage III esophageal adenocarcinoma patients treated with neoadjuvant CXRT with or without induction chemotherapy at our institution. After examining for eligibility, we excluded patients that were medically inoperable (n=27), had distant disease progression (n= 21), or died (n=6) during neoadjuvant therapy. These 153 patients successfully completed chemoradiation and were considered candidates for curative resection after restaging and evaluation. We further excluded definitive chemoradiation patients who later underwent salvage surgery for local recurrence (n=5) and surgery cases that were terminated upon discovery of liver metastasis at initial laparotomy (n=5). As shown in Fig. 1 , a remaining 143 patients were included in the analysis.
Treatment
Among the 143 patients included in the analysis, 114 underwent surgery and 29 did not. The most common reasons for refusing surgery were patient choice and physician choice (e.g., physician preference for observation and/or no referral to surgeon). 9 Most patients who did not undergo surgery had a favorable response to therapy and were considered complete clinical responders. Patients received a median radiation dose of 50.4 Gy (range, 36-50.4 Gy; Table 1 ). Chemotherapy regimens were most commonly a platinum doublet consisting of 5-flourouracil plus cisplatin or oxaliplatin vs. a taxane/platinum combination. A small majority of patients (80, 55.9 %) received induction chemotherapy followed by concurrent CXRT compared to concurrent CXRT (63, 44.1 %; Table 1 ).
Esophagectomy was typically performed 6-8 weeks after completion of CXRT. The majority of patients (74/114, 64.9 %) underwent a right transthoracic esophagectomy (Table 1) . Perioperative mortality was low, with only five (4.4 %) treatmentrelated deaths within 90 days of surgery. Operative morbidity was also low. Among the surgery patients, 21 (18.4 %) had a major pulmonary event (defined as postoperative pneumonia and/or reintubation and/or pulmonary embolus and/or acute respiratory distress syndrome). There were 13 (11.4 %) anastomotic leaks, the majority of which were grade I (5/13, 35.7 %) or grade II (5/13, 35.7 %) that required no or mild intervention (e.g., drain, stent), respectively. Nineteen (16.7 %) patients had a pathologic complete response.
Patient Characteristics
Patients in the two treatment groups had similar demographic and tumor characteristics, with the exception of age (Table 1) . Definitive CXRT patients were more likely to be older, with a median age of 70 years (range, 48-83 years); however, patients in both groups had similar comorbidity scores.
Overall and Disease-Free Survival As shown in Table 2 , poorly differentiated tumors and treatment with surgery were the only significant predictors of OS. Patients treated with surgery saw a 50 % risk reduction in overall mortality. Median OS was significantly improved (41.2 vs. 20.3 months, p=0.012) among patients treated with surgery (Fig. 2) . This finding did not change in the sensitivity analysis when salvage resections (n=5) were added to the definitive CXRT group (41.2 vs. 20.3 months, p=0.011; Fig. 3 ).
Poorly differentiated tumors and treatment with surgery were also significant predictors of DFS, as was a SUV≥8.75 on post-treatment PET (Table 3) . DFS was significantly improved with the addition of surgery (21.5 vs. 11.4 months, p=0.007; Fig. 2 ). Surgery provided a 46 % reduced risk of cancer-specific mortality.
Using propensity score matching to match patients on age, comorbidity score, tumor length, tumor grade, post-CXRT biopsy, and post-CXRT SUV, median OS was significantly better among surgery patients (45.7 vs. 20.3 months, p=0.033; Fig. 4 ). Due to patients with missing post-treatment SUV, propensity matching was done on 48 patients (24 CXRT+surgery, 24 definitive CXRT).
Clinical Responders
The majority of patients (125, 87.4 %) had pre-and post-CXRT PET scans available to evaluate clinical response to CXRT. We identified 86 responders (19 definitive CXRT, 67 surgery) and 39 non-responders (all treated with surgery). Ten definitive CXRT patients did not have evaluable PET scans or biopsy results to classify them according to our response algorithm. These patients were often considered clinical responders by the treating physician (thus prompting observation vs. further treatment with surgery). Among clinical responders (n=86), patients treated with surgery had significantly improved median OS (45.7 vs. 20.9 months, p=0.043; Fig. 5 ).
Discussion
Our study is the first to compare treatment with definitive CXRT to CXRT followed by surgery in exclusively adenocarcinoma patients that are eligible for trimodality therapy. Although there are other studies that appear similar to ours, [14] [15] [16] progression of disease during neoadjuvant CXRT. Because the inclusion criteria may have biased the results of these studies in favor of surgery, an analysis of properly selected patients was critical to establishing a survival benefit. We found that in a cohort of trimodality-eligible patients with locally advanced esophageal adenocarcinoma, patients treated with CXRT followed by surgery saw significant advantages in median OS and DFS compared to patients treated with definitive CXRT.
These findings clarify a previously undefined clinical benefit and transform the clinical discussion that takes place after a patient successfully completes CXRT. What is the potential value of additional locoregional therapy with surgery after response to CXRT? Patients with locally advanced, resectable esophageal adenocarcinoma (cStage III) frequently receive treatment with neoadjuvant CXRT, and the majority demonstrates favorable response to therapy. 7, [16] [17] [18] [19] To date, we lacked adequate data to estimate the additional benefit 11 (10) Minimally invasive 18 (16) of surgery after successful completion of CXRT. Existing evidence promoted surgery as an integral component of successful trimodality therapy 20 and established that surgery significantly improves locoregional control as compared to definitive CXRT. [21] [22] [23] However, an inability to reference the specific survival contribution of surgery may have encouraged exclusion of resection as part of multimodality therapy. This study adds further evidence that the additional benefit in locoregional control afforded by surgery may translate into significant gains in overall survival. For patients contemplating further treatment with surgery after CXRT, knowledge of a specific mortality reduction with the addition of surgery will 24 patients were treated with CXRT followed by randomization to further medical or surgical therapy based on barium swallow findings of response to treatment. The study enrolled almost exclusively esophageal squamous cell carcinoma (SCCA) patients (11 % glandular cancer) and reported no benefit in overall survival with the addition of surgery. However, a significant number of patients were eliminated from the randomization, and patients who were later treated with salvage surgery were analyzed on an intent-to-treat basis. Similarly, a German collaborative trial 25 randomized patients to treatment with induction chemotherapy and concurrent CXRT with or without surgery. Among patients with SCCA (adenocarcinoma patients were primarily excluded), there was no reported benefit for overall survival in the surgery arm compared to definitive CXRT. Criticism of this trial would suggest that it was underpowered; there is a clear trend in overall survival favoring the surgery arm that does not reach significance, and disease-free survival was significantly improved among surgery patients. Treatment-related mortality in both trials was excessive in the surgery arm, negating the potential benefit of surgery. Despite these shortcomings and potential dissimilarities between adenocarcinoma and SCCA, trials describing definitive therapy for esophageal cancer have likely influenced the utilization of definitive CXRT for locally advanced adenocarcinoma in non-protocol settings. Yet, given the observed differences in response rates to CXRT, 20 we must consider the treatment of adenocarcinoma as distinct from that of SCCA.
Although our study may be the first to quantify the additional benefit from surgery, several limitations and cautions should be noted. First, this is a retrospective observational Fig. 2 Median overall survival and disease-free survival of trimodality-eligible patients with locally advanced esophageal adenocarcinoma treated with chemoradiation followed by surgery compared to definitive chemoradiation (n=148). For the disease-free survival analysis, we included five definitive chemoradiation patients who were later treated with salvage resections to fully account for local recurrences in this treatment group Fig. 3 Median overall survival of trimodality-eligible patients with locally advanced esophageal adenocarcinoma treated with chemoradiation followed by surgery compared to definitive chemoradiation, including salvage resections (n=148) study with a limited sample size. These results reflect the experience of a single institution with high surgical volume and a multidisciplinary service dedicated to esophageal cancer. Our findings may not be generalizable to clinical settings that have higher rates of perioperative morbidity and mortality, which may reduce or negate the benefit of surgery we observed in our study. Validation of our results in a larger, multi-institutional setting is ideal. The patients in our study were not randomized to treatment with bimodality or trimodality therapy, which may have introduced a selection bias. To address this limitation, we made every effort to include only patients that were considered surgical candidates after completing neoadjuvant therapy and used important prognostic variables in the propensity matched analysis. However, we should not ignore the possibility that there may be subgroups of patients with aggressive tumor biology who will not benefit from additional locoregional therapy with surgery. In both the OS and DFS multivariable analyses, poorly differentiated tumors and high post-treatment SUV were independently associated with poorer survival. When we stratified the analysis by post-treatment SUV, surgery still provided significant improvements in overall survival (27.3 vs. 9.5 months, p= 0.006) in the subgroup of patients with the highest SUV (≥8.75; data available in the Electronic Supplementary Material (ESM)). Although the number of patients in this subgroup may be too small to reach valid conclusions, the findings are consistent with our previous work indicating that surgery improves the outcomes of patients with high SUV after CXRT. 26 In addition, we compared the overall survival of patients with poorly differentiated tumors, which demonstrated significant survival advantages among patients treated with surgery (32.8 vs. 16.7 months, p=0.003; data available in the ESM). Despite the tendency to consider the influence of high SUV and/or poorly differentiated tumors as overwhelming the potential benefit of surgery, these exploratory analyses suggest that surgery still provides significant improvements in survival for patients with aggressive tumor biology. We must consider the results cautiously, though, as our study was not designed or adequately powered to examine the interaction of prognostic variables on survival in subgroups of patients who did or did not undergo surgery. This requires a more complex or full factorial trial design with a much larger sample size.
Finally, our findings also do not preclude selective surgery for patients who do well with CXRT. Patients treated with definitive CXRT in our study reached an OS and DFS plateau at 20 %, suggesting that some patients may be destined for complete pathological response and are ultimately cured without surgery. Although we found that there was a benefit to surgery in both matched and unmatched patient populations, as well as the subgroup analysis of clinical responders, there may be a point at which the additional risk of surgery may outweigh the potential benefit for an individual patient. There may be several indications for initially considering trimodality therapy with surgery but later electing to stop treatment after completing CXRT. Neoadjuvant therapy may serve as a physiologic challenge for patients who are considered "borderline" candidates for surgery at initial staging and evaluation. Planning for trimodality therapy utilizes CXRT as an additional assessment of risk that may avoid unnecessarily resecting patients who cannot tolerate surgery. In certain cases, salvage Fig. 4 Median overall survival of trimodality-eligible patients with locally advanced esophageal adenocarcinoma treated with chemoradiation followed by surgery compared to definitive chemoradiation using propensity score matching (n=48). Patients were matched on age, comorbidity, tumor length, tumor grade, post-treatment biopsy, and post-treatment SUV Fig. 5 Median overall survival of trimodality-eligible patients with locally advanced esophageal adenocarcinoma who achieved a clinical response to neoadjuvant therapy treated with chemoradiation followed by surgery compared to definitive chemoradiation (n=86) resection could be used after locoregional failure of definitive CXRT if the performance status is adequate. This selective approach to resection may prove to be a versatile algorithm to therapy, but this decision must take place within a multidisciplinary setting that includes surgical input. Further study is necessary to better characterize precisely which patients should be considered for initial resection and which would benefit from selective approaches to surgery.
Conclusion
Surgery should be considered an integral component of effective trimodality therapy for locally advanced esophageal adenocarcinoma. Further prospective study is warranted prior to adopting treatment regimens that omit surgery, either entirely or selectively.
